Additionally, dabrafenib (GSK2118436), designed for mutated BRAFs, and trametinib, a specific MEK 1/2 inhibitor, gained FDA approval in 2013 as individual treatments for metastatic melanoma with BRAF mutations. Here, BRAF is linked to metastatic melanoma.